

ION PATH WEBINAR DIZA 1B ASSES

16 JUNE 2021 - 16:00-18:00 CEST (UTC +2), Webinar held live

WELCOME AND INTRODUCTION 16:00

Nicola Normanno

IQN Path President and Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy

16:05 **CHALLENGES IN TMB TESTING**

Albrecht Stenzinger

ESP Speaker, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany

TECHNICAL SOLUTIONS FOR TMB ASSESSMENT 16:20

Presentations by the companies that actively participated in the research:

16:20 David Fabrizio

Foundation Medicine, VP, Translational Strategy, Cambridge, MA, United States

16:30 Joe Whittaker

Illumina, Staff Marketing Manager, Clinical Oncology, EMEA, Cambridge, United Kingdom

16:40 Raed Samara

Qiagen, Director Product Management Oncology and Precision Diagnostics, Washington, United States

16:50 Andrea Luchetti

Thermo Fisher Scientific, EMEA Market Development Manager Oncology, Rome, Italy

RESULTS OF THE IQN PATH PILOT EQA FOR TMB TESTING 17:00

Riziero Esposito Abate

Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy

CHALLENGES IN CLINICAL IMPLEMENTATION OF TMB AS BIOMARKER 17:15

Sanjay Popat

Royal Marsden Hospital and the Institute of Cancer Research, London, United Kingdom

17:30 **DISCUSSION**

CONCLUSIONS 17:50

18:00 Close

This EQA has been provided as an IQN Path collaboration between several EQA providers including AIOM, GenQA, EMQN, ESP QA Foundation, Gen&Tiss, CiQc/CBQA and RCPAQAP.

View the programme

Registration is free of charge and can be processed online from the website **here**

For further information, please contact <u>executive@iqnpath.org</u>

PROVIDER AND LOGISTIC SECRETARIAT

